Mersana Therapeutics Announces Appointment of Martin H. Huber, M.D., to Board of Directors
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Martin H. Huber, M.D., to its Board of Directors, effective immediately. “We are extremely excited to bring in a new board member with such deep experience in oncology drug development. Marty’s track record in developing transforming medicines for both ovarian and lung cancer patients is unparalleled,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “We will greatly benefit from his expertise as we progress XMT-1536 through proof of concept and into registration-enabling studies.” Dr. Huber most recently served as Senior Vice President and Chief Medical Officer at TESARO, Inc. before its acquisition by GSK. While at TESARO, he dr
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- How Mersana's Acquisition Is Changing the Story and Analyst Outlook for Investors [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSNBusiness Wire
- How the Acquisition Is Reshaping Mersana Therapeutics' Story and Analyst Outlook [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.MarketBeat
MRSN
Earnings
- 11/14/25 - Miss
MRSN
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 12/4/25 - Form SC
- MRSN's page on the SEC website